Carbapenem-containing combination antibiotic therapy against carbapenem-resistant uropathogenic Enterobacteriaceae.
The increasing global prevalence of carbapenem-resistant Enterobacteriaceae (CRE) combined with the decline in effective therapies is a public healthcare crisis. After respiratory tract infections, urinary tract infections and associated urosepsis are the second most affected by CRE pathogens. By using checkerboard analysis, we tested eight different antibiotics in combination with carbapenems in CAMHB and artificial urine against seven CRE and three susceptible strains. To further determine whether these combinations are also effective in a dynamic model, we have performed growth curves analyses in a dynamic bladder model with three uropathogenic CRE strains. In this model we simulated the urinary pharmacokinetic after application of 1000 mg i.v. ertapenem alone or in combination with 500 mg i.v. levofloxacin, 1000 mg oral rifampicin or 3000 mg oral fosfomycin. Bacterial growth was measured for 48 h, simulating voiding of the bladder every 3 h. According to the median fractional inhibitory concentration indices (∑FICI) values we found additive to synergistic results across all tested CRE strains for combinations of carbapenems with colistin sulphate, levofloxacin, fosfomycin, rifampicin and tigecycline in CAMHB and artificial urine. In the dynamic bladder model, all three CRE strains tested showed regrowth after treatment with ertapenem up to 48 hours. Regrowth could be prevented by combination with levofloxacin, fosfomycin or rifampicin. Carbapenem-containing combination therapy with fosfomycin or rifampicin could be an option for better treatment of UTIs caused by CRE strains. This should be further investigated in clinical studies.